Source丨Healthnews21 Original Work
Author/Han Liming
EditEditor/Ji Yuanyuan
More than four years after leaving Hengrui Pharma (600276.SH), Zhou Yunshu's new employment update has surfaced.Recently, the "Official Platform of Jiangsu Cancer Hospital" released information showing that the "Key Laboratory of Advanced Diagnosis and Treatment of Malignant Tumors in Jiangsu Province" at Jiangsu Cancer Hospital (Affiliated Cancer Hospital of Nanjing Medical University) has officially signed a strategic cooperation agreement with Simcere's "National Key Laboratory of Neurology and Oncology Drug Development." Zhou Yunshu attended in his capacity as "President of Simcere Pharmaceutical Group."Market speculation suggests that Zhou Yunsu has been appointed as the Group President of Simcere (02096.HK), a Hong Kong-listed innovative pharmaceutical company. Some media reports also state that Zhou Yunsu’s current appointment is as the President of Jiangsu Simcere Pharmaceutical Co., Ltd. According to Simcere's annual report, Jiangsu Simcere Pharmaceutical Co., Ltd. is an indirectly wholly-owned subsidiary of the listed company Simcere Group Limited.As of now,Simcere has not yet issued an official announcement regarding Zhou Yunshu's appointment, and the details of the appointment are still pending further disclosure by the official sources.In fact,As the year comes to an end and a new one begins, the pharmaceuticals industry is witnessing a wave of intensive executive changes.Guoxin Zhu, with over 30 years of global cross-functional drug discovery leadership experience, has joined Hengrui Pharma; Yu Xiang, who has served as the president of multinational pharmaceutical companies' China region and as the CEO of innovative drug enterprises, has joined BRL Medicine; Ningshu Liu, who has held positions such as Co-Chief Scientific Officer of Fosun Pharma Global R&D and Chief Researcher of Bayer Germany's Oncology Research Department, has taken up a new role at Asieris..."A senior executive of a listed pharmaceutical company told the 21st Century Business Herald, 'The flow of core talents with management experience in multinational pharmaceutical companies within the industry can not only bring advanced management systems to local enterprises but also introduce mature R&D processes and internationalized operation models, laying a critical talent foundation for local innovative pharmaceutical companies to break through the bottlenecks of global development.'"In the industry's view, the underlying reasons for the recent密集变动of pharmaceutical company executivesReflecting the current situation of local pharmaceutical companies directly facing the global wave of innovative drugs, the industry trend of proactively implementing strategic adjustments and optimizing the layout of core talent will further drive the innovation, upgrading, and globalization of China's pharmaceuticals sector.
Hengrui Pharma Veteran"Airdrop"Zhou Yunshu was a veteran figure at Hengrui Pharma.Public information shows that in 1995, after graduating from China Pharmaceutical University, Zhou Yunshu joined Hengrui Pharma, successively serving as Deputy Minister of Development, Vice General Manager, General Manager, and Director. In January 2020, he succeeded Sun Piaoyang, the founder who had led the company for 30 years, to become the Chairman of the Eighth Board of Directors.In an alleged internal speech by Sun Piaoyang that circulated in the industry at the time, Zhou Yunshu was acknowledged as the "best candidate" to take over. "Zhou Yunshu has been serving as the general manager since 2003, managing all aspects of operations and overseeing sales. Sales present significant challenges for pharmaceutical companies in China."However, this helm career did not last long. In July 2021, Zhou Yunshu applied to resign from his positions as Chairman, General Manager, and corresponding duties in specialized committees of the board of Hengrui Pharma due to health reasons, and Sun Piaoyang returned to take over the company.After leaving his position, Zhou Yunshu's whereabouts remained a mystery for some time. It was not until the end of 2024 that Zhou Yunshu was mentioned on the official website of Jiangsu Provincial Cancer Hospital in a report about the "Symposium on Pharmaceutical Enterprises," identifying him as the "Head of Global Market Access at Innovent Biologics."However, Innovent Biologics did not issue an official announcement regarding his appointment, and this professional association ultimately remained at the level of market speculation.Now, Zhou Yunshu may officially embark on a new professional chapter. Simcere, established in 1995, was listed on the Hong Kong Stock Exchange on October 27, 2020. According to the disclosure on Simcere's official website, founder Ren Jinsheng serves as chairman and chief executive officer; Wang Xi serves as executive director and vice president, overseeing human resources, supply chain, and other areas; Wang Feng serves as party secretary and senior vice president, responsible for research and development and collaborative innovation businesses; Wu Yihan (Goh Ak Han) serves as senior vice president and chief medical officer, leading clinical development.
In recent years, Simcere has been advancing its innovative transformation with strong momentum. In the first half of 2025, Simcere's revenue increased by 15.14% year-on-year to 3.585 billion yuan, and its net profit rose by 32.2% year-on-year to 604 million yuan. The company’s commercialized innovative drug portfolio has expanded to 10 products, covering neuroscience, oncology, autoimmune diseases, and anti-infective fields. During the same period, revenue from innovative drugs reached 2.776 billion yuan, accounting for 77.4% of total revenue.In terms of external cooperation and internationalization strategy, Simcere has made frequent moves in 2025. In January, it reached a collaboration with Guangzhou Femi子, obtaining exclusive rights to develop and commercialize the clinical-stage analgesic candidate innovative drug FZ002-037 in the Greater China region (Mainland China, Hong Kong, Macao, and Taiwan). In the same year, it signed an agreement with Wangshan Wangshui to gain exclusive licensing rights for the use of Dihydrogen Bromide Remdesivir Dry Suspension in treating Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (HMPV) infections in the Greater China region.Moreover, by the end of 2025, Simcere's subsidiary, Simcere Zaiming, reached an exclusive global licensing agreement (excluding Greater China) with French company Ipsen for SIM0613, an antibody-drug conjugate (ADC) with best-in-class potential.Simcere has achieved four out-licensing deals for self-developed innovative drugs, with a total authorized transaction value of nearly $3.4 billion.As the news of Zhou Yunshu's appointment continues to ferment, the market is paying close attention to when Simcere will officially announce the details of his appointment. The collaboration between this veteran of the pharmaceuticals industry and an innovative drug company is expected to bring new changes to the industry, which is worth continued anticipation.
Chinese Pharmaceutical Companies Focus on Global Talent LayoutAs Zhou Yunshu assumes his new role, Hengrui Pharma also faces a critical personnel change.By the end of 2025, Hengrui Pharma appointed Guoxin Zhu as Senior Vice President. According to available information, Guoxin Zhu has over 30 years of global cross-functional leadership experience in drug discovery, covering all stages from target hypothesis to early clinical testing and spanning multiple disease areas including diabetes/obesity and their complications, immunology, neurological disorders, pain, and oncology.His resume shows that Zhu Guoxin served as the Vice President of Eli Lilly's New Drug Research and Development Center, leading multiple discovery research and early development projects. He served as the chairman of the Small Molecule Strategy Team, overseeing the research and delivery of more than 100 small molecule clinical drug candidates. At the same time, he was also a core member of the Therapeutic Area Strategy Team, contributing to the portfolio and external collaboration research strategies across multiple modalities (small molecules, peptides, antibodies, and siRNA).In the industry's view, the core value of Zhu Guoxin's joining lies in the strategic vision of building cutting-edge technology platforms such as ADC, bispecific/multi-specific antibodies, and small nucleic acid drugs, which is expected to inject mature experience into Hengrui Pharma's innovative R&D system.Personnel Changes at Hengrui Pharma and Simcere Are Not Isolated Cases,Recently, a wave of senior executives with multinational backgrounds has joined China's innovative pharmaceutical companies.Starting from January 1, 2026, Dr. Xiang Yu will officially join BRL Medicine, serving as the Chief Executive Officer. He will be fully responsible for the company's strategic planning, resource allocation, and overall operational management, accelerating the clinical translation and market implementation of multiple cutting-edge gene and cell therapy products globally.Public information shows that Yu Xiang once served as the president of a multinational pharmaceutical company's China branch and the CEO of an innovative pharmaceutical company, holding key leadership positions. He possesses comprehensive strategic planning, business growth, and commercialization implementation capabilities. He has made significant achievements in innovative pipeline layout, NDA approval, new product launches, NRDL negotiations and multi-channel access, as well as digital ecosystem construction. He is skilled at driving corporate transformation and sustainable development with a global perspective.Asieris alsoRecently, Dr. Ningzhu Liu was appointed as the Chief Scientific Officer to comprehensively oversee the strategic planning and implementation of early drug discovery at Asieris, the establishment of innovative drug R&D technology platforms, and to jointly drive the expansion of the innovative drug pipeline and external collaborations.; In addition, market sources indicate that Jin Xiaodong, the former General Manager of Pfizer China's Strategic Alliance Division, has recently joined Shanzhe Pharmaceuticals, an innovative drug company incubated by Sequoia China. However, this appointment has not yet been officially confirmed by the relevant parties.Behind the密集变动 of senior executives lies the strategic主动调整 of本土药企 in the context of the global wave of innovative drugs. In 2025, China's pharmaceutical industry will reach a milestone: a total of 76 innovative drugs approved throughout the year, with对外授权 transactions amounting to over $130 billion, both figures setting new historical records. The profound changes in the industry environment impose higher requirements on the能力结构 of pharmaceutical companies' executive teams.An industry insider told the 21st Century Business Herald: "Centralized procurement, medical insurance, intensified product competition, and shortened life cycles have made both Chinese and foreign pharmaceutical companies face more severe cost control and efficiency evaluation pressures. Against this backdrop,Multinational pharmaceutical companies are accelerating their focus on potential blockbuster fields, while local innovative drug companies are gradually gaining recognition from multinational pharmaceutical companies due to their advantages in R&D speed and efficiency. The Chinese market has become a core element of the global pharmaceutical supply chain.The joining of senior executives with multinational pharmaceutical backgrounds to local enterprises lays a core talent foundation for local pharmaceutical companies to break through the bottlenecks of global development."The personnel adjustments at the turn of the year have already set the stage for industry transformation. As these new leaders with a global perspective officially assume their roles, whether local pharmaceutical companies can achieve new breakthroughs in innovative R&D and global layout, and deliver a "new answer" to high-quality development, is highly anticipated by the market.Image/21 Image Library
Typesetting/Xu Qiulian
[Copyright Statement] All content in this article is copyrighted by 21st Century Economic Report. No part may be reproduced, excerpted, or used in any other form without permission.
